INTRODUCTIONProstate cancer screening is accomplished by digital rectal examination (DRE) and serum prostate‐specific antigen (PSA) testing in at risk populations. Men with an elevated age‐specific serum PSA, serum PSA velocity of >0.35 ng/mL per year, or abnormal DRE are believed to be at risk for harboring occult prostate cancer thereby warranting discussion about the merits of prostate needle biopsy. The serum PSA test, however, has limitations in that non‐malignant conditions such as benign prostatic hyperplasia (BPH) and prostatic inflammation can generate non‐specific PSA elevations. Therefore, a high PSA may theoretically yield unnecessary prostate biopsy with resultant complications including infection, bleedings, urinary retention, and pain. Additional concerns entail the psychological stress about possibly having prostate cancer. Therefore, more specific biomarkers for prostate cancer are needed to make a more accurate recommendation for prostate biopsy.MicroRNAs (miRNAs) are small non‐coding RNAs that have the potential to be biomarkers for prostate cancer. They regulate gene expression, post‐transcriptionally, by targeting messenger RNA (mRNAs) and inhibiting their translation. They have been shown to be either down‐regulated or up‐regulated in cancers as well as involved in cellular processes that influence tumorigenesis such as differentiation, proliferation, and apoptosis, thus suggesting their role in cancers. For prostate cancer, studies
The Prostate – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera